Merck, Schering-Plough Complete Merge

Print Email Add to Favorites RSS

Merck & Co. Inc. has outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation.

"With our merger now complete, we are ready to deliver on the promise of a new Merck built on a foundation of scientific innovation and dedication to the well-being of patients around the world," said Richard T. Clark, chairman, president and chief executive officer of Merck. "On 'Day One' for the new Merck, we are stronger and better equipped to make a difference in the lives of people globally through our broadened, diversified portfolio of innovative medicines and vaccines, and products for consumer and animal health."

Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, and animal and consumer health products.

Merck now has approximately 106,000 employees and operates in more than 140 countries around the world, including emerging markets. The company expects to generate more than 50% of its revenue outside the United States.

The company's corporate headquarters will be in Whitehouse Station, N.J. In addition, the company's U.S. organization for the Global Human Health division and Merck Research Laboratories will be headquartered in Upper Gwynedd, Pa. The former Schering-Plough headquarters in Kenilworth, N.J., and Merck's operations in Rahway, N.J., will continue to be important sites, with large and diverse operations encompassing marketing, manufacturing, and research. At this time, all other sites will continue to operate as they did before the merger.

Merck's Animal Health business is a world leader with market-leading products for a broad range of species and strong growth potential. The division has more than 1,000 marketed products and generates approximately $3 billion in revenues.

During the past six months, Merck and Schering-Plough merger integration teams worked hard to successfully maintain the business momentum of the two companies while ensuring operational readiness and business continuity for the merged company.

The company's organizational structure takes advantage of the combined strengths of Merck and Schering-Plough to create a more customer-focused, innovative, and diversified global health care company positioned to capitalize on the company's greatest opportunities for growth, particularly in emerging markets, biologics, and vaccines. Merck has five primary divisions: Global Human Health, Animal Health, Consumer Health Care, Merck Research Laboratories, and Merck Manufacturing.

With the merger complete, Merck will take a global approach to unify and simplify use of its trade name. The company will use the trade name "Merck" in the United States and Canada and elsewhere use the trade name "MSD."